Wright Adrienne, Arthaud-Day Marne L, Weiss Mark L
Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, United States.
Department of Management, Kansas State University, Manhattan, KS, United States.
Front Cell Dev Biol. 2021 Feb 16;9:632717. doi: 10.3389/fcell.2021.632717. eCollection 2021.
Following their discovery over 50 years ago, mesenchymal stromal cells (MSCs) have become one of the most studied cellular therapeutic products by both academia and industry due to their regenerative potential and immunomodulatory properties. The promise of MSCs as a therapeutic modality has been demonstrated by preclinical data yet has not translated to consistent, successful clinical trial results in humans. Despite the disparities across the field, MSC shareholders are unified under one common goal-to use MSCs as a therapeutic modality to improve the quality of life for those suffering from a malady in which the standard of care is suboptimal or no longer effective. Currently, there is no Food and Drug Administration (FDA)-approved MSC therapy on the market in the United States although several MSC products have been granted regulatory approval in other countries. In this review, we intend to identify hurdles that are impeding therapeutic progress and discuss strategies that may aid in accomplishing this universal goal of widespread therapeutic use.
间充质基质细胞（MSCs）在50多年前被发现后，因其再生潜力和免疫调节特性，已成为学术界和工业界研究最多的细胞治疗产品之一。临床前数据已证明MSCs作为一种治疗方式的前景，但尚未转化为人类一致、成功的临床试验结果。尽管该领域存在差异，但MSCs的支持者们有一个共同的目标，即使用MSCs作为一种治疗方式，以改善那些患有标准治疗效果欠佳或不再有效的疾病的患者的生活质量。目前，美国市场上尚无食品药品监督管理局（FDA）批准的MSCs疗法，尽管几种MSCs产品已在其他国家获得监管批准。在本综述中，我们旨在确定阻碍治疗进展的障碍，并讨论可能有助于实现广泛治疗应用这一普遍目标的策略。
